Assessment report for Bydureon (exenatide) 28 June 2018, EMA/700805/2018.
"No environmental risk assessment has been performed. This is acceptable and in line with the CHMP guideline which states that peptides are exempted from such assessment."
Fass environmental information for Bydureon from AstraZeneca (downloaded 2019-10-15).
The use of amino acids, proteins and peptides is not considered to have any environmental impact.
According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00), vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids proteins, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.
Author: Health and Medical Care Administration, Region Stockholm